Recently, it was learned that Biotech Pharmaceuticals Co., Ltd. developed Contezolid (MRX-I) and its prodrug Contezolid Acefosamil (MRX-4) for the treatment of acute skin and skin soft tissue infections caused by bacteria, and was supervised by the US Food and Drug Administration. The FDA has passed the fast track certification of qualified anti-infective disease products.
The treatment of MRSA infection is one of the most difficult clinical problems, the key is that it is multi-drug resistant to many antibiotics. MRSA is the most common multi-drug resistant human bacterial pathogen in the world. It can cause infections in the skin, lungs, blood and joints and can lead to death.
Dr. Mike Goldyev, Chief Scientific Officer of Allied Medicine, said: "This FDA's determination confirms the need for new drugs for MRSA and vancomycin-resistant Enterococcus."
Bacteria such as "multi-drug resistant bacteria" can have strong resistance to antibiotics and can escape the danger of being killed. Because most antibiotics do not work for them, it is extremely harmful to human health. The prevalence of sex bacteria, the development of new antibiotics or new treatments is even more urgent. The development cycle of new antibiotics is long, and the development rate of bacterial resistance is much faster than the development speed of new drugs.
It is understood that according to the US Antibiotic Development and Incentive Act, the development of high-priority antibacterial pathogens has a rapid examination qualification.
Medical Equipment Disposal,Syringes Needles Sizes,Disposable Syringe,Insulin Syringe
FOSHAN PHARMA CO., LTD. , https://www.pharmainjection.com